Vicinivax Announces Last Patient Out In The Phase I Study With Immunotherapy Vvax001 ...

ViciniVax is pleased to report today that the last patient has completed treatment in the Phase I study with Vvax001. This study was designed to assess the safety and HPV16 E6,7-specific T-cell immune responses upon injection of 4 different doses of Vvax001 in a total of 12 subjects. Full analysis of the data is expected in Q2 2018.